8-K: C4 Therapeutics Reports Positive Clinical Trial Updates and Financial Results for 2024

C4 Therapeutics announces financial results for 2024 and provides updates on its clinical programs, including cemsidomide and CFT1946, with plans to initiate new clinical trials in early 2026.

Summary

• C4 Therapeutics reported its fourth quarter and full year 2024 financial results and provided business updates.
• The company is planning activities for the next phase of cemsidomide clinical development in multiple myeloma and non-Hodgkins lymphoma, with trials expected to start in early 2026.
• The CFT1946 Phase 1/2 trial is progressing across multiple cohorts, with data in melanoma and colorectal cancer expected in the second half of 2025.
• As of December 31, 2024, C4 Therapeutics had $267.3 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2027.
• Total revenue for 2024 was $35.6 million, compared to $20.8 million for the prior year.
• Research and development expenses for 2024 were $110.6 million, compared to $117.7 million for the prior year.
• Net loss for 2024 was $105.3 million, compared to $132.5 million for the prior year.
• The company expects its cash position to fund its operating plan into 2027.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with promising clinical data and a solid financial position. While there are losses, the company is making progress and has a clear path forward.

Positives

• Cemsidomide showed promising response rates in multiple myeloma and non-Hodgkins lymphoma clinical trials.
• CFT1946 demonstrated the ability to cross the blood-brain barrier in preclinical studies.
• CFT8919 entered clinical development in Greater China.
• The company has a strong cash position of $267.3 million, providing a runway into 2027.
• Revenue increased to $35.6 million for the year ended December 31, 2024, compared to $20.8 million for the prior year.

Negatives

• The company reported a net loss of $105.3 million for the year ended December 31, 2024.
• Cash, cash equivalents, and marketable securities decreased from $281.7 million as of December 31, 2023, to $267.3 million as of December 31, 2024.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include uncertainties related to the initiation, timing, advancement, and conduct of preclinical and clinical studies.
• There is a risk that the company's product candidates may not be successfully developed and commercialized.
• The company faces the risk that sufficient capital to fund future operations will not be available on acceptable terms or at the times required.

Future Outlook

C4 Therapeutics plans to advance its clinical programs, including cemsidomide and CFT1946, and initiate new clinical trials in early 2026. The company expects its current cash position to fund operations into 2027.

Management Comments

• Andrew Hirsch, president and chief executive officer of C4 Therapeutics, stated that the company made significant progress across its degrader portfolio and discovery collaborations in 2024.
• He also mentioned the company's focus on unlocking the value of cemsidomide and generating data from the Phase 1 trials of CFT1946 and CFT8919 to inform future development strategies.

Industry Context

C4 Therapeutics is operating in the competitive biopharmaceutical industry, focusing on targeted protein degradation. The company's progress in clinical trials and collaborations with major pharmaceutical companies like Merck and Biogen positions it as a notable player in the field.

Comparison to Industry Standards

• C4 Therapeutics' approach to targeted protein degradation is similar to that of companies like Arvinas and Kymera Therapeutics, which are also developing degrader molecules for various diseases.
• The reported ORR of 36% for cemsidomide in combination with dexamethasone in multiple myeloma is within the range of other therapies used in this setting, such as proteasome inhibitors and immunomodulatory drugs.
• The cash runway into 2027 is a positive sign, as many biotech companies need to raise additional capital more frequently.

Management Changes

Stakeholder Impact

• Shareholders: The positive clinical data and financial stability are likely to be viewed favorably by shareholders.
• Employees: The company's progress and financial runway provide job security for employees.
• Patients: The development of new therapies offers hope for improved treatment options for patients with cancer.

Next Steps

• Complete Phase 1 dose escalation and present data in MM and NHL for cemsidomide in the second half of 2025.
• Open expansion cohort(s) in PTCL as part of the current Phase 1/2 trial for cemsidomide in the second half of 2025.
• Present Phase 1 data for CFT1946 in the second half of 2025.
• Enable initiation of the next phase of clinical development for MM and PTCL, with new studies expected to initiate in early 2026.

Key Dates